Colonic neoplasm
MONDO:0005401A benign or malignant neoplasm that affects the colon. Representative examples of benign neoplasms include lipoma and leiomyoma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma. Colonic adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms.
Also known as: colon neoplasm, colon neoplasm (disease), colon tumor, colon tumour, colonic neoplasm, colonic tumor, colonic tumour, neoplasm of colon
2070 clinical trials for this condition and its sub-types, 461 tagged with Colonic neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Colonic neoplasm
-
Malignant colon neoplasm 62 trials · 439 incl. sub-types
9 sub-types
- Colon carcinoma 279 trials · 379 incl. sub-types Sub-types →
- Cecum cancer 0 trials · 53 incl. sub-types Sub-types →
- Metastasis from malignant tumor of colon 27 trials
- Sigmoid colon cancer 9 trials · 14 incl. sub-types Sub-types →
- Ascending colon cancer 9 trials · 10 incl. sub-types Sub-types →
- Transverse colon cancer 2 trials
- Descending colon cancer 0 trials · 1 incl. sub-types Sub-types →
- Colon lymphoma 0 trials Sub-types →
- Colon sarcoma 0 trials Sub-types →
-
Epithelial tumor of colon 0 trials · 409 incl. sub-types
4 sub-types
- Colon carcinoma 279 trials · 379 incl. sub-types Sub-types →
- Epithelial tumor of the appendix 0 trials · 42 incl. sub-types Sub-types →
- Colon adenoma 17 trials · 32 incl. sub-types Sub-types →
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
-
Cecal neoplasm 0 trials · 59 incl. sub-types
5 sub-types
- Appendiceal neoplasm 30 trials · 56 incl. sub-types Sub-types →
- Cecum cancer 0 trials · 53 incl. sub-types Sub-types →
- Cecum neuroendocrine tumor G1 3 trials Sub-types →
- Benign neoplasm of cecum 0 trials Sub-types →
- Cecum villous adenoma 0 trials Sub-types →
-
Sigmoid neoplasm 7 trials · 17 incl. sub-types
2 sub-types
- Sigmoid colon cancer 9 trials · 14 incl. sub-types Sub-types →
- Rectosigmoid junction neoplasm 0 trials · 5 incl. sub-types Sub-types →
-
Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types
3 sub-types
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
- Appendix neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Colon small cell neuroendocrine carcinoma 0 trials
-
Benign colon neoplasm 2 trials
5 sub-types
- Benign neoplasm of cecum 0 trials Sub-types →
- Cavernous hemangioma of colon 0 trials
- Colon leiomyoma 0 trials Sub-types →
- Colonic lymphangioma 0 trials
- Lipoma of colon 0 trials
-
Colon inflammatory polyp 0 trials
-
Colon juvenile polyp 0 trials
Most studied deeper sub-types
-
Can your own immune cells beat advanced cancer?
Cure Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase 1/2 • Sponsor: Gritbio Medicine, Inc. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Custom-Made cancer vaccine enters early human testing
Vaccine Not yet recruitingThis study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …
Early phase 1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New injectable drug tested for safety in Hard-to-Treat solid tumors
Disease control Not yet recruitingResearchers are running a phase 1 trial of SHR-4595, an experimental injectable drug, in adults with advanced solid tumors that have not responded to standard treatments. The study checks how safe and tolerable the drug is, how the body processes it, and what dose might work best…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
Can colorectal surgery patients go home in two days?
Disease control Not yet recruitingResearchers are studying whether patients can safely leave the hospital within 48 hours after minimally invasive colorectal surgery. The trial follows 97 adults having elective laparoscopic or robotic surgery for benign or malignant disease. It checks how many meet predefined cli…
Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
Disease control Not yet recruitingResearchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…
Phase 1 • Sponsor: AIMEDBIO • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New injectable drug tested against Hard-to-Treat solid tumors
Disease control Not yet recruitingResearchers are running a Phase I trial of HEC-921, an experimental drug given by intravenous infusion, in adults with advanced malignant solid tumors. The study first gives HEC-921 alone to find the highest dose people can tolerate, then tests it in combination with oxaliplatin,…
Phase 1 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can precision radiation and immunotherapy team up against abdominal colorectal cancer?
Disease control Not yet recruitingResearchers are testing whether adding targeted radiation plus the immunotherapy drug cadonilimab to standard second-line chemotherapy helps adults with colorectal cancer that has spread only to the peritoneum. The trial enrolls about 198 participants and randomly assigns them to…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
A Two-Target antibody takes aim at advanced solid tumors
Disease control Not yet recruitingResearchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…
Phase 1 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a targeted drug conjugate outsmart advanced colorectal cancer?
Disease control Not yet recruitingThis phase 1 trial tests an investigational drug called DEM301 in adults with advanced colorectal cancer that has progressed after standard treatments. DEM301 is an antibody-drug conjugate, a type of therapy designed to deliver a toxic agent directly to cancer cells. The study ai…
Phase 1 • Sponsor: DEM BioPharma, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a Two-Drug immunotherapy combo shrink MSS colon cancer before surgery?
Disease control Not yet recruitingThis phase 2 trial tests whether giving two immunotherapy drugs, pembrolizumab and porustobart, before surgery can shrink tumors in adults with a common type of colon cancer called MSS (microsatellite stable) that has not spread. Participants receive the drugs through a vein, wit…
Phase 2 • Sponsor: Solstice Oncology, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a coordinated care team reduce severe side effects in older cancer patients?
Disease control Not yet recruitingThis trial tests whether a coordinated care pathway, involving oncologists, geriatricians, pharmacists, and pharmacologists, can reduce severe side effects in adults over 70 with certain cancers who are starting oral therapy. Participants receive extra monitoring, including blood…
Phase 4 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Tumor-Directed injection shrink Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…
Phase 1 • Sponsor: Parr Biotechnology (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Two-Pronged drug attack Hard-to-Treat tumors?
Disease control Not yet recruitingThis first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…
Phase 1 • Sponsor: Biolojic Design Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new Immune-Boosting drug shrink advanced solid tumors?
Disease control Not yet recruitingThis Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat digestive tumors?
Disease control Not yet recruitingThis study tests an experimental drug called BL-M08D1 in adults with advanced or metastatic digestive tract tumors and other solid tumors. The goal is to find the best dose and see how well it shrinks tumors and slows disease progression. Participants receive the drug by intraven…
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new injection shrink advanced solid tumors?
Disease control Not yet recruitingThis phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…
Phase 1/2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Immunotherapy combo aims to shrink colon tumors before surgery
Disease control Not yet recruitingThis study tests whether two immunotherapy drugs, cemiplimab and fianlimab, can safely shrink colon tumors before surgery in people with stage II-III colon cancer that hasn't spread. Participants get two IV doses before surgery, then are followed for up to three years. The goal i…
Phase 2 • Sponsor: John Strickler, M.D. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new immunotherapy combo tame aggressive appendiceal cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining the experimental immunotherapy drug ivonescimab with chemotherapy (paclitaxel) delivered directly into the abdomen can safely and effectively treat people with high-grade metastatic appendiceal adenocarcinoma that cannot be removed…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Long-Acting immune booster help fight advanced solid tumours?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…
Phase 1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental virus therapy takes on Drug-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…
Phase 1 • Sponsor: Bionoxx Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new pill outsmart mutant cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…
Phase 1 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Not yet recruitingThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Not yet recruitingThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can immune cells shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…
Phase 1 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn childhood cancers
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Misted chemotherapy shows promise for Hard-to-Treat abdominal cancers
Disease control Not yet recruitingThis phase 3 trial tests a new method called PIPAC that delivers chemotherapy as a pressurized mist directly into the abdomen during a minimally invasive procedure. It compares this approach plus standard intravenous chemo (FOLFIRI) to standard chemo alone for people with appendi…
Phase 3 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Dual-Targeting drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…
Phase 1/2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase 1/2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase 1/2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Organ transplant may offer new hope for rare abdominal cancer patients
Disease control Not yet recruitingThis study tests whether an intestinal or multivisceral transplant can help people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that cannot be removed by surgery. Twenty participants will receive the transplant and be followed for 12 months to see if they surv…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Personalized cell therapy takes on Hard-to-Treat tumors
Disease control Not yet recruitingThis early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…
Phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Electric pulses and diet: a new weapon against muscle loss in stomach and bowel cancers?
Disease control Not yet recruitingThis trial tests whether a combination of whole-body electromyostimulation (WB-EMS) — a technology that uses electrical impulses to make muscles contract — and nutritional therapy can help people with certain gastrointestinal cancers preserve muscle mass. Participants include tho…
Sponsor: University of Cologne • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…
Phase 1/2 • Sponsor: BrYet US, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New cancer pill enters first human tests
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…
Phase 1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental drug TJ037130 takes aim at advanced solid tumors
Disease control Not yet recruitingThis phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…
Phase 1 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Oral drug elraglusib aims to tame advanced solid tumors
Disease control Not yet recruitingThis study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…
Phase 1/2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…
Phase 1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a common parasite drug boost cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug KIVU-305 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…
Phase 1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New PARP1 inhibitor targets Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …
Phase 1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThis trial investigates whether combining two drugs—trastuzumab deruxtecan (T-DXd) and cetuximab—can shrink tumors in people with advanced colorectal cancer that has low levels of the HER2 protein and has worsened after standard treatments. The study enrolls adults with metastati…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Speed test: which heat tool best seals colon polyp removal sites?
Disease control Not yet recruitingThis trial compares two techniques—snare tip soft coagulation and hybrid APC—used to burn the edges of the wound after removing large colon polyps. The goal is to see which method is faster while still preventing polyps from coming back. About 140 adults with large non-cancerous …
Sponsor: Western Sydney Local Health District • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered herpes virus takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…
Phase 1/2 • Sponsor: Virogin Biotech Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Bicycle therapies offer continued hope for advanced tumors
Disease control Not yet recruitingThis trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…
Phase 2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo aims to boost surgery success in colon cancer
Disease control Not yet recruitingThis phase 2 trial is testing whether giving two drugs—Zanzalintinib and Retifanlimab—before surgery can help patients with early-stage colon cancer. The study enrolls adults aged 18 to 80 with a type of colon cancer called pMMR that can be removed surgically. Participants receiv…
Phase 2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental T-Cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …
Early phase 1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug LNF2105 enters first human trials
Disease control Not yet recruitingThis early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…
Phase 1 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immunotherapy may let some GI cancer patients skip the knife
Disease control Not yet recruitingThis study looks at whether immunotherapy can shrink certain gastrointestinal cancers (like colorectal or stomach cancer) enough that some patients may not need major surgery. People whose tumors have specific genetic features (MSI-H/dMMR or POLE mutation) and who respond well to…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental injection trains immune cells inside the body to fight cancer
Disease control Not yet recruitingThis early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase 1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail aims to make inoperable liver metastases removable
Disease control Not yet recruitingThis study tests whether adding an experimental immunotherapy drug (QL1706) to standard chemotherapy and radiation can shrink liver tumors from colon cancer enough to allow surgery. About 30 adults with colon cancer that has spread only to the liver will receive the combination b…
Phase 2 • Sponsor: Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Not yet recruitingThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase 1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…
Phase 2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Blood test could personalize chemo breaks for advanced colon cancer
Disease control Not yet recruitingThis phase 3 trial tests whether a blood test that measures tumor DNA (ctDNA) can help doctors decide when to reduce or switch chemotherapy in people with metastatic colorectal cancer. About 408 participants will be randomly assigned to either standard treatment or a strategy whe…
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New antibody drug aims to outsmart tumors by targeting two immune pathways
Disease control Not yet recruitingThis study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …
Phase 1/2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Phase 1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy takes on advanced cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …
Early phase 1 • Sponsor: Peking University Shenzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug Hemay5087 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…
Phase 1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection targets cancer fluid in lungs and belly
Disease control Not yet recruitingThis early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…
Phase 1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo drug trial hopes to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug CS231295 enters first human trial for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …
Phase 1 • Sponsor: ThalassaX Therapeutics United States Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New combo aims to shrink tough colon cancers before surgery
Disease control Not yet recruitingThis phase II trial tests whether a stronger chemotherapy cocktail (cmFOLFOXIRI) plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemotherapy (mFOLFOX6) when given before surgery for locally advanced colon cancer. About 138 patients with high-risk stage II …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New liposome drug takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…
Phase 1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug IN10028 tested for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…
Phase 1 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug 'Unmasks' cancer cells to immune system in early trial
Disease control Not yet recruitingThis early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…
Phase 1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase 4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SYS6051 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.
Phase 1 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingThis study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug FXB0871 takes on advanced cancers in first human trial
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Virus cocktail takes on tough liver tumors
Disease control Not yet recruitingThis phase 2 trial tests whether injecting an oncolytic virus (H101) directly into liver tumors, along with radiation, chemotherapy, targeted therapy, and immunotherapy, can shrink or control colorectal cancer that has spread to the liver and cannot be removed by surgery. The stu…
Phase 2 • Sponsor: Jun Huang • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a heart drug boost colon cancer treatment?
Disease control Not yet recruitingThis study tests if adding a common heart medication (propranolol) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a certain type of colon cancer. About 45 adults with stage II or III colon cancer that is mismatch repair proficient (…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Snake venom protein tested as cancer treatment in humans
Disease control Not yet recruitingThis early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…
Phase 1 • Sponsor: Celtic Biotech Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cancer: ALK-N001 enters human trials
Disease control Not yet recruitingThis study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…
Phase 1/2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cancer drug targets HER3 in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …
Phase 1/2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for tough colon cancer: fruquintinib trial launches in south korea
Disease control Not yet recruitingThis study tests a drug called fruquintinib in 88 adults with advanced colon cancer that has not responded to standard chemotherapies. The goal is to see if adding supportive care to manage side effects can help patients live longer without their cancer growing. Participants will…
Phase 2 • Sponsor: Korea University Anam Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to shrink liver tumors for surgery
Disease control Not yet recruitingThis phase II trial tests a chemotherapy regimen called FULIRI, combined with either bevacizumab or cetuximab, as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so they can be surgically removed. The study will …
Phase 2 • Sponsor: Zhongnan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New taxane drug RP-001 enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …
Phase 1/2 • Sponsor: Recurv Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New cancer drug SIG001 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…
Phase 1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy targets Stomach-Lining cancer in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug combination (PX plus nab-paclitaxel) given directly into the abdomen for people with a type of advanced cancer that has spread to the lining of the belly. The main goal is to find a safe dose and check for side effects. About 22 adults with…
Phase 1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug QLS5308 enters human testing for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…
Phase 1/2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug T320 targets tough tumors in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…
Phase 1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could immunotherapy spare some colon cancer patients from surgery?
Disease control Not yet recruitingThis study tests giving an immunotherapy drug (pembrolizumab) before surgery to people with a specific type of colon cancer (dMMR). The goal is to see if the drug can shrink or eliminate the tumor so some patients may avoid surgery and instead be closely monitored. About 152 adul…
Phase 2 • Sponsor: Ismail Gögenur • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could Pre-Surgery chemo boost survival in colon cancer?
Disease control Not yet recruitingThis study compares giving chemotherapy before surgery versus standard surgery-first treatment for people with stage II or III colon cancer that has a high CEA level. About 100 adults aged 18-70 will be randomly assigned to one of two groups. The goal is to see if pre-surgery che…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called KT032 in 24 adults with advanced solid tumors (ovarian, mesothelioma, colon cancer) that have spread to the abdomen and haven't responded to standard treatments. The main goal is to check safety and find the best dose, while …
Early phase 1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered macrophages take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cell therapy aims to train immune system against hard-to-treat cancers
Disease control Not yet recruitingThis early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a vaccine made from your own tumor stop colon cancer from returning?
Disease control Not yet recruitingThis Phase 3 trial tests a personalized cancer vaccine called OncoVAX for people with Stage II colon cancer. After surgery to remove the tumor, the patient's own cancer cells are used to create a vaccine that trains the immune system to attack any remaining cancer cells. The goal…
Phase 3 • Sponsor: Vaccinogen Inc • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Keeping patients at the right temperature during surgery may protect their brain
Disease control Not yet recruitingThis study tests whether a step-by-step plan to manage body temperature during a long surgery can lower the chance of postoperative delirium (sudden confusion). The surgery is for a rare abdominal tumor called pseudomyxoma peritonei and involves heated chemotherapy. The trial wil…
Sponsor: Aerospace Center Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for advanced colon cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug combination (HLX43 plus HLX07 or serplulimab) in people with advanced or metastatic colorectal cancer that has stopped responding to standard first-line treatment. About 126 participants will receive the experimental therapy to see if it can shrink tum…
Phase 1/2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Microtransplantation: a new hope for advanced cancer patients?
Disease control Not yet recruitingThis early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …
Phase 1 • Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a smart thermometer protect kids on chemo from dangerous fevers?
Disease control Not yet recruitingThis study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Supercharged T-Cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …
Early phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FXS887 enters first human tests for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug HX111 enters early human trials
Disease control Not yet recruitingThis study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…
Phase 1/2 • Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo aims to fix Chemo-Caused low platelets
Disease control Not yet recruitingThis Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill takes on advanced cancers in early human trial
Disease control Not yet recruitingThis study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New injection after liver ablation aims to stop colorectal cancer in its tracks
Disease control Not yet recruitingThis study tests whether a new drug called IP-001, injected into the liver after standard heat-based tumor destruction, can help prevent colorectal cancer from coming back. About 717 adults with colorectal cancer that has spread only to the liver will be randomly assigned to rece…
Phase 2/3 • Sponsor: Immunophotonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a new pill tame immunotherapy's worst side effects and let patients restart treatment?
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for rare cancers: china launches massive drug trial
Disease control Not yet recruitingThis study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…
Phase 1/2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill targets cancer growth pathway in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…
Phase 1/2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New gene therapy trial hopes to tame advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…
Phase 1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Mushroom-Derived compound joins forces with radiation and immunotherapy to fight advanced cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…
Phase 2 • Sponsor: Second Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill hopes to fight multiple cancers when other treatments fail
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…
Phase 1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for tough cancers: experimental drug TB511 enters human trials
Disease control Not yet recruitingThis early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…
Phase 1/2 • Sponsor: Twinpig Biolab, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New mRNA vaccine takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…
Phase 1/2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drain technique aims to reduce complications after rectal cancer surgery
Disease control Not yet recruitingThis study compares a new drain fixation method (extra-peritoneal tunneling) to the standard method after rectal cancer surgery. About 596 participants will be randomly assigned to one of the two groups. The goal is to see if the new method reduces drain movement and improves the…
Sponsor: Yeungnam University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New gene therapy trial hopes to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …
Phase 1 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug ATB-320 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…
Phase 1 • Sponsor: Autotelicbio • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Custom immune attack: new gene therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …
Phase 1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug aims to fix Chemo-Induced low platelets
Disease control Not yet recruitingThis study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…
Sponsor: Jun wang • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Second chance: drug combo retested for tough colorectal cancer
Disease control Not yet recruitingThis phase 2 trial is testing whether giving the drugs encorafenib and cetuximab again can help people with a specific type of advanced colorectal cancer (BRAF V600E-mutant) whose disease got worse after prior treatment with similar drugs. About 25 participants will receive the d…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 26, 2026 18:05 UTC
-
Surgeons test artificial valve to stop diarrhea after colon cancer removal
Disease control Not yet recruitingThis study tests a new surgical procedure called RISE that rebuilds the ileocecal valve during right colon cancer surgery. Normally, removing this valve can cause diarrhea and malnutrition. The trial will randomly assign 188 patients to either receive the valve reconstruction or …
Sponsor: Army Medical University, China • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC
-
New drug combo aims to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…
Phase 1/2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:39 UTC
-
New combo therapy aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
New drug cocktail aims to shrink colon tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy can shrink tumors before surgery in people with stage III colon cancer that is microsatellite stable (pMMR/MSS). About 21 participants will receive four cycles of th…
Phase 2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 26, 2026 14:11 UTC
-
New hope for cancer patients: drug may fix Radiation-Related low platelets
Disease control Not yet recruitingThis phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…
Phase 2 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:03 UTC
-
New camera modes could sharpen Colonoscopy's eye for precancerous polyps
Diagnosis Not yet recruitingThis trial tests two new imaging modes, VIST and SFI, during colonoscopy to see if they help doctors find and classify colorectal polyps better than standard white light. About 990 adults undergoing screening or surveillance colonoscopy will be randomly assigned to one of the thr…
Sponsor: Alexandre Vontobel Padoin • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
A simple breath test might spot multiple cancers before symptoms appear
Diagnosis Not yet recruitingThis trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Can a new imaging tracer outperform standard scans in finding hidden tumors?
Diagnosis Not yet recruitingThis trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
Dye-Free laser imaging could replace standard dye in colorectal surgery
Diagnosis Not yet recruitingThis study compares two imaging methods for checking blood flow to the bowel during colorectal surgery: the standard technique using a dye called indocyanine green (ICG) and a newer dye-free method called Laser Speckle Contrast Imaging (LSCI). About 30 adults having elective colo…
Sponsor: Leiden University Medical Center • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New Dual-Targeted PET scan aims to spot cancers more clearly
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Dye spray boosts Colonoscopy's hidden polyp detection
Diagnosis Not yet recruitingThis study tests whether spraying a mix of acetic acid and indigo carmine dye during colonoscopy helps doctors find more precancerous polyps (called sessile serrated lesions) in the right side of the colon compared to standard white-light colonoscopy. About 2,689 adults aged 45-8…
Sponsor: Changhai Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New device may help spot hidden precancerous polyps
Diagnosis Not yet recruitingThis study tests a new device that flattens colon polyps before they are examined under a microscope. The goal is to help doctors better identify sessile serrated lesions, a type of polyp that can lead to colorectal cancer. About 1,156 adults having polyps removed during a colono…
Sponsor: Changhai Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New 'Smart' PET scan could spot hidden cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
3D maps could sharpen colon cancer surgery
Diagnosis Not yet recruitingThis study tests whether a 3D computer model, made from a standard CT scan, helps surgeons better plan operations for locally advanced colon cancer. About 168 adults with stage cT3 or cT4 colon cancer will be randomly assigned to have surgery planned with or without the 3D model.…
Sponsor: Fundació d'investigació Sanitària de les Illes Balears • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Could a simple scan replace biopsies for cancer immunotherapy?
Diagnosis Not yet recruitingThis study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Blood markers may spot colorectal cancer earlier
Diagnosis Not yet recruitingThis study aims to see if measuring two proteins in the blood, Talin-1 and Cripto-1, can help diagnose colorectal cancer. Researchers will compare these levels in 70 newly diagnosed patients and healthy people. The goal is to find a simpler, more accurate way to detect the diseas…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
AI reads CT scans to guide colon cancer treatment
Diagnosis Not yet recruitingThis study aims to improve how doctors classify colon tumors by using artificial intelligence (AI) to analyze CT scans. The AI will be trained to tell early-stage tumors from advanced ones and to detect lymph node involvement, which is key for deciding on treatments like chemothe…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
Stool test could spot colon cancer early, study hopes
Diagnosis Not yet recruitingThis study will check how well a non-invasive stool test (quantitative fecal immunochemical test, or qFIT) can detect colorectal cancer and precancerous lesions like adenomas and serrated polyps. Researchers will compare the test results with colonoscopy findings in 150 adults ag…
Sponsor: Sohag University • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
AI boosts colonoscopy: finding hidden cancer clues
Diagnosis Not yet recruitingThis study tests whether an artificial intelligence (AI) tool can help doctors spot precancerous growths in the upper part of the colon during a colonoscopy. About 1,200 people with symptoms like belly pain, constipation, or black stools will take part. The goal is to see if usin…
Sponsor: Limian Er • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Can a new drug wipe out hidden cancer DNA and stop colorectal cancer from returning?
Prevention Not yet recruitingResearchers are testing an experimental drug called INCA33890 in people with stage II or III colorectal cancer who have finished surgery and chemotherapy but still have tiny amounts of tumor DNA in their blood. This leftover DNA, called circulating tumor DNA or ctDNA, can signal …
Phase 2 • Sponsor: Incyte Corporation • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Mailed stool tests could boost colon cancer screening
Prevention Not yet recruitingThis study tests whether providing educational materials and mailing stool-based screening kits (FIT or Cologuard) to primary care patients can increase colorectal cancer screening rates. Participants aged 45-75 who are eligible for screening will be assigned to receive education…
Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
New trial aims to slash deadly bloodstream infections from hospital tubes
Prevention Not yet recruitingThis study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…
Sponsor: The University of Queensland • Aim: Prevention
Last updated Jul 19, 2026 00:00 UTC
-
SAMe supplement may shield liver from chemo harm
Prevention Not yet recruitingThis study tests whether taking S-adenosylmethionine (SAMe), a natural supplement, can prevent liver injury caused by the chemotherapy drug oxaliplatin. About 30 adults with colorectal cancer that has spread to the liver will take SAMe pills daily for 3-6 months alongside their c…
Phase 2 • Sponsor: Cedars-Sinai Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Can kitchen oils beat chemo side effects? new study tests sesame oil and aloe vera
Prevention Not yet recruitingThis study compares three topical treatments—sesame oil, aloe vera gel, and nitroglycerin ointment—against no treatment for preventing phlebitis (vein inflammation) caused by chemotherapy. Researchers will enroll 190 adults with breast or colon cancer receiving specific chemo dru…
Phase 2 • Sponsor: University of Basrah • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
New program aims to boost cancer screening in syrian migrant community
Prevention Not yet recruitingThis study tests a culturally tailored educational program to help Syrian migrants in Turkey get screened for breast, cervical, and colorectal cancers. About 30 participants will take part in the program, which uses a questionnaire to measure their motivation and knowledge before…
Sponsor: Toros University • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Glutamine supplement may shield kids from chemo nerve pain
Prevention Not yet recruitingThis study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…
Phase 3 • Sponsor: Ain Shams University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
Live music meets virtual reality: can a Three-Session program reach advanced cancer patients in palliative care?
Symptom relief Not yet recruitingResearchers at Hospital Universitario Austral in Argentina are testing whether a structured three-session music therapy program called MUSPAL360 can be delivered to hospitalized adults with advanced cancer receiving palliative care. The program combines live music therapy with 36…
Sponsor: Austral University, Argentina • Aim: Symptom relief
Last updated Sep 21, 2026 15:00 UTC
-
Can a new drug shield kidneys from chemotherapy damage?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…
Phase 1 • Sponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a psychedelic ease the existential weight of advanced cancer?
Symptom relief Not yet recruitingThis pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…
Phase 2 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Talking through memories may lighten the load for dementia caregivers
Symptom relief Not yet recruitingThis study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
A lifeline for cancer caregivers: can simple phone support reduce their stress?
Symptom relief Not yet recruitingThis pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
AI therapy coach aims to ease distress in seriously ill seniors
Symptom relief Not yet recruitingThis study tests whether an AI-powered program can help older adults with serious illnesses like cancer or heart disease manage emotional distress. Participants receive short videos and daily check-ins from a chatbot that teaches practical coping skills, all from their own phone.…
Phase 1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Gut bacteria may shield nerves from chemo damage – a trial puts it to the test
Symptom relief Not yet recruitingThis phase III trial tests whether a daily probiotic supplement, OXXYSLAB®, can reduce peripheral neuropathy—nerve damage causing pain and numbness—in people with stage III colon cancer receiving oxaliplatin-based chemotherapy (FOLFOX or XELOX). About 130 participants will take e…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
New program aims to give veterans with advanced cancer a stronger voice in their End-of-Life care
Symptom relief Not yet recruitingThis study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Gentle belly massage may speed gut recovery after colon cancer surgery
Symptom relief Not yet recruitingThis trial investigates whether gentle abdominal massage, performed early after colon cancer surgery, can help the intestines start working again more quickly. Many patients experience a temporary slowdown in gut function (postoperative ileus) that causes bloating, pain, and naus…
Sponsor: University Hospital, Grenoble • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Ice chips vs. mouth sores: simple trick may ease chemo side effect
Symptom relief Not yet recruitingThis study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…
Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Dance away chemo pain: new study tests fun exercise for nerve damage
Symptom relief Not yet recruitingThis study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …
Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
No opioids, less confusion? new study for seniors having gut surgery
Symptom relief Not yet recruitingThis study looks at whether using a drug combination without opioids during anesthesia can lower the chance of confusion (delirium) after surgery in people 65 and older having gastrointestinal surgery. About 174 participants will be randomly assigned to receive either opioid-free…
Phase 1 • Sponsor: Qianfoshan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Remote exercise program aims to boost chemo completion in cancer patients
Symptom relief Not yet recruitingThis study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…
Sponsor: AdventHealth Translational Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Simple exercises may soothe chemo nerve damage
Symptom relief Not yet recruitingThis study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…
Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Miracle fruit may bring back taste for cancer patients
Symptom relief Not yet recruitingThis pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Can acupuncture needles Kick-Start a paralyzed stomach after cancer surgery?
Symptom relief Not yet recruitingThis study tests whether electroacupuncture (mild electrical pulses through thin needles) can help patients whose stomachs stop working properly after surgery for digestive tract tumors. Seventy-six adults who had such surgery and developed gastroparesis (stomach paralysis) will …
Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Exercise before and during chemotherapy may boost treatment success
Symptom relief Not yet recruitingThis study tests whether a supervised exercise program, started two weeks before chemotherapy and continued for 16 weeks during treatment, can help adults aged 35 to 65 with breast, lung, or colon cancer tolerate chemotherapy better. The goal is to see if participants can receive…
Sponsor: University of Vic - Central University of Catalonia • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Could probiotics tame Chemo's worst symptoms?
Symptom relief Not yet recruitingThis study tests whether taking probiotic supplements can help reduce common chemotherapy side effects like nausea, diarrhea, and loss of appetite in people with stage III colon cancer. Forty adults will be randomly assigned to receive either probiotics or a placebo during their …
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Herbal soak may soothe Chemo's painful side effects
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…
Sponsor: Peking University Third Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New All-in-One monitor aims to make surgery safer for colon cancer patients
Symptom relief Not yet recruitingThis study tests a new device called Medstrom that monitors pain, sedation, and muscle relaxation all in one during laparoscopic colon cancer surgery. Thirty patients will be randomly assigned to either the Medstrom device or standard monitoring. The goal is to see if the device …
Sponsor: Chinese PLA General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Can video calls replace clinic visits for palliative care?
Symptom relief Not yet recruitingThis study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…
Sponsor: Al Al Bayt University, Jordan • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Can tracking symptoms improve care for children with advanced cancer?
Knowledge-focused Not yet recruitingThis observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
A simple leg lift could forewarn dangerous blood pressure drops in surgery
Knowledge-focused Not yet recruitingThis study tests whether a simple bedside maneuver—raising the legs—combined with ultrasound of the carotid artery can predict if a patient will experience a sudden drop in blood pressure after anesthesia is given. It involves adults undergoing elective surgery for gastrointestin…
Sponsor: Ankara City Hospital Bilkent • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
A new clue in the fight against colorectal cancer recurrence?
Knowledge-focused Not yet recruitingThis study looks at whether a combination of immune cell activity, genetic changes, and imaging features can help predict if colorectal cancer that has spread to the liver will come back after surgery. Researchers will analyze tumor tissue, blood samples, and scans from about 210…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can artificial intelligence think like a cancer tumor board?
Knowledge-focused Not yet recruitingThis study asks whether an artificial intelligence system can make the same care recommendations as a team of cancer experts for people with stomach, colon, or rectal cancer. About 69 participants will have their medical information reviewed independently by both the AI and a mul…
Sponsor: Shanghai Minimally Invasive Surgery Center • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase 2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Polyp recurrence after colon cancer surgery: a clue to better Follow-Up?
Knowledge-focused Not yet recruitingThis study looks at 3,000 people who had surgery for colorectal cancer to see how often polyps come back in the colon afterward. Researchers will check if the type and stage of the original cancer are linked to polyp recurrence. The goal is to improve follow-up care by identifyin…
Sponsor: Gansu Provincial Hospital • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New scan could spot hidden cancer left behind after liver surgery
Knowledge-focused Not yet recruitingThis study investigates whether a special 3D MRI scan, called magnetic resonance elastography (3D-MRE), can detect microscopic tumor remnants at the surgical margin after liver cancer removal. Current methods only examine the removed tissue, not the remaining liver. Researchers w…
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Simple blood draws could predict colon cancer treatment success
Knowledge-focused Not yet recruitingThis study investigates whether two blood-based biomarkers—circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP)—can predict how well colon cancer responds to pre-surgery therapy. About 80 adults with stage III colon cancer will provide extra blood samples before, duri…
Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
AI could outshine standard tumor measurements to predict survival
Knowledge-focused Not yet recruitingThis study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Study seeks clues to predict who needs closer colon checks after polyp removal
Knowledge-focused Not yet recruitingThis study looks at people who have had certain types of colon polyps (serrated lesions) removed. It aims to find out why some of them later develop new advanced growths in the colon. By tracking 750 adults over time, researchers hope to identify risk factors that could help doct…
Sponsor: Changhai Hospital • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Blood test and AI team up to outsmart colon cancer recurrence
Knowledge-focused Not yet recruitingThis study explores whether combining artificial intelligence analysis of tumor tissue with special blood tests (liquid biopsy) can more accurately predict if colon cancer will return after surgery. Researchers will follow 400 adults with stage II or III colon cancer for up to fi…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Could skipping bowel prep before colon surgery be just as safe?
Knowledge-focused Not yet recruitingThis study looks at whether it's safe to skip mechanical bowel preparation (the drink that cleans out your colon) before colon surgery. Currently, the best practice combines that drink with antibiotics to prevent infections. The trial will compare two groups: one getting the drin…
Sponsor: Mount Sinai Hospital, Canada • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden cancer cells
Knowledge-focused Not yet recruitingThis study is testing whether a green dye called indocyanine green (ICG) can help surgeons see and remove lymph nodes that contain cancer during laparoscopic colon cancer surgery. About 25 adults with colon cancer will receive the dye injected around the tumor and into a vein. Th…
Sponsor: Tanta University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists map hidden paths of colorectal cancer spread
Knowledge-focused Not yet recruitingThis study looks at where cancer spreads to lymph nodes in people with colon or rectal cancer. Researchers will examine tissue from 1200 patients who had surgery to remove their cancer. The goal is to find patterns that could help doctors better plan treatment in the future.
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks polyp return rates to improve Follow-Up care
Knowledge-focused Not yet recruitingThis study looks at how often polyps in the stomach or colon grow back after being removed during a scope procedure. Researchers will follow about 2,000 adults for up to three years to track recurrence and identify risk factors like polyp size, lifestyle, and health history. The …
Sponsor: LanZhou University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New AI-Powered CT scan could sharpen colon cancer detection
Knowledge-focused Not yet recruitingThis study will test a new way to create CT images for people with colon cancer. The method uses deep learning to make the images clearer. Researchers will compare the quality of these new images to standard ones. The goal is to see if this technique helps doctors see tumors bett…
Sponsor: Philips Clinical & Medical Affairs Global • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Blood test may spare thousands from unnecessary colon surgery
Knowledge-focused Not yet recruitingThis study will collect blood samples from 1,000 people with small colon growths to see if a liquid biopsy can accurately tell benign from malignant lesions and predict cancer spread to lymph nodes. Current methods often lead to unnecessary surgery. The goal is to create a bioban…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Counseling after positive cancer blood test studied
Knowledge-focused Not yet recruitingThis study looks at how decision counseling affects people who get a positive result on the Shield blood test for colorectal cancer. Researchers want to see if counseling helps reduce confusion and increases the chance of getting a follow-up colonoscopy. About 350 adults aged 45-…
Sponsor: Guardant Health, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Does breakfast change how chemo works? new study investigates
Knowledge-focused Not yet recruitingThis early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…
Phase 1 • Sponsor: Health Hope Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Tumor DNA in fluids may predict peritoneal metastasis risk
Knowledge-focused Not yet recruitingThis study looks at whether tumor DNA found in blood or peritoneal fluid can predict the spread of digestive cancers (stomach, colon, pancreas) to the lining of the abdomen. Researchers will follow 300 patients with early-stage tumors to see if those with positive DNA markers are…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Could your gut bacteria predict colon Cancer's return?
Knowledge-focused Not yet recruitingThis study looks at whether certain bacteria in your stool can help predict if colon cancer will come back after surgery. Researchers will collect stool and blood samples from 107 adults before and after their surgery. They want to see if bacteria that break down collagen are lin…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Can a simple quiz spot frailty in older cancer patients?
Knowledge-focused Not yet recruitingThis study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…
Sponsor: Hospital de Braga • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists hunt for biological clues to Cancer-Related anxiety and depression
Knowledge-focused Not yet recruitingThis study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…
Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New study aims to predict who benefits from abdominal cancer surgery
Knowledge-focused Not yet recruitingThis study looks at how colorectal cancer grows when it spreads to the lining of the abdomen. Researchers want to see if the pattern of tumor growth can help doctors decide who will benefit most from surgery. The study will follow 30 adults who are already scheduled for surgery o…
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Could cancer antibodies trigger heart problems? new study investigates
Knowledge-focused Not yet recruitingThis study will check if people with metastatic breast or colon cancer have antibodies that might also attack the heart. Researchers will collect blood samples and ECGs from 196 participants over 12 months. The goal is to see if these antibodies raise the risk of dangerous heart …
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Keyhole surgery vs open surgery for colon cancer: which is better?
Knowledge-focused Not yet recruitingThis study compares two types of surgery for right-sided colon cancer: laparoscopic (keyhole) surgery and open surgery. The goal is to see which approach leads to less blood loss, fewer complications, and a shorter hospital stay. The study will include 22 adults with right colon …
Sponsor: Kafrelsheikh University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
AI eye in the colon: new study aims to catch hidden polyps
Knowledge-focused Not yet recruitingThis study tests whether a computer-aided detection system can help doctors find more polyps in the right side of the colon during a colonoscopy. About 686 adults aged 40-75 will have two colonoscopies in one session, with the AI system used in one of them. The goal is to see if …
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Exercise study aims to unlock biological secrets in cancer care
Knowledge-focused Not yet recruitingThis study looks at how a personalized strength training program affects people with different cancers, including lung, colon, breast, and blood cancers. 150 adults will either do supervised strength training plus home exercises, or just home exercises, for 12 weeks. Researchers …
Sponsor: University of Salamanca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
AI boosts colonoscopy rates in china trial
Knowledge-focused Not yet recruitingThis study tests whether artificial intelligence (AI) can help more high-risk adults aged 40 to 64 get colonoscopies to screen for colorectal cancer. About 400 participants will be split into two groups: one gets usual care, the other gets AI-assisted support from doctors and nur…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New registry aims to decode mysterious immune side effects of cancer drugs
Knowledge-focused Not yet recruitingThis study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New tool to measure Cancer's financial toll tested in turkey
Knowledge-focused Not yet recruitingThis study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…
Sponsor: Akdeniz University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Gut check: could your microbiome predict fertility after immunotherapy?
Knowledge-focused Not yet recruitingThis observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …
Sponsor: West China Second University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Real-world test of adebrelimab combo for tough cancers
Knowledge-focused Not yet recruitingThis study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…
Sponsor: Tianjin First Central Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:13 UTC
-
New blood test aims to predict who will respond to immunotherapy
Knowledge-focused Not yet recruitingThis study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:54 UTC
-
New study aims to pinpoint Cancer's hidden path in colon surgery
Knowledge-focused Not yet recruitingThis observational study will examine lymph nodes from the ileum mesentery in 406 people undergoing surgery for right-sided colon cancer. Researchers want to learn where cancer spreads in these nodes to help surgeons decide how much tissue to remove. Participants will be followed…
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:20 UTC